Your Search Returned 87 tagged news reports
In the more distant past, the model used when assessing Teva was to look at it as a unit that included several profit centers. The analyst would look at each unit individually viz-a-viz its respective market and at the end of the process he would summarize...
Tags: Teva Pharmaceutical Industries Ltd., Tysabri, Elan Corp., Copaxone, Pfizer Inc., New York City, Ivax Corporation, Pharmaceutical industry, Natalizumab, Generic drug, Pharmaceutical companies, Teva Pharmaceutical Industries, Glatiramer acetate, Business Finance
Pfizer Inc's next- generation Prevnar vaccine missed some of the main goals in a study testing its ability to protect against bacteria that cause ear infections, pneumonia and other diseases, U.S. reviewers said in documents released on Monday. Pfizer...
Tags: Pfizer Inc, FDA, Food and Drug Administration, Zavesca, Bethesda, Metabolic disorders, Rare diseases, Miglustat, Niemann¬タモPick disease, Gaucher's disease, Orphan drugs, Genetic disorders, Lipid storage disorders, Health Medical Pharma, Wyeth, Pfizer, Pneumococcal vaccine, Vaccines, Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine, Infectious diseases, Vaccination, Streptococcus pneumoniae, Pneumonia, Microbiology, Pharmaceutical companies
A new study suggests that thousands of heart failure deaths and hospitalizations may be averted each year if doctors prescribe higher doses of a critical medication, researchers here said Tuesday. The medication, called an angiotensin-receptor blocker,...
Tags: heart failures, permanent treatment, Pfizer Inc, heart pumping, Orlando, Torcetrapib, High-density lipoprotein, Atherosclerosis, Aging-associated diseases, Pfizer, Cardiology, Cardiovascular diseases, Angiology, Health Medical Pharma, Interventional cardiology, Prosthetics, Ventricular assist device, HeartMate, Pump, Implants, Artificial organs, Angiotensin II receptor antagonist, Heart failure, Beta blocker, Antihypertensive agents, ACE inhibitors, Transplantation medicine, Pharmaceutical companies, Anacetrapib, Cholesterylester transfer protein, Lipoproteins, Dow Jones Industrial Average
After drug giant Pfizer Inc. announced that it was opening a new research center here, city officials aggressively moved to acquire surrounding land for an economic development project — triggering an epic fight over eminent domain that reached the U.S.
Tags: Pfizer Inc., eminent domain, New London Development Corporation, Paty Daignault, research center, private development, New London, Kelo v. City of New London, Dana Berliner, Groton Connecticut, New London Connecticut, Kelo, Business Finance, New London County Connecticut, Pfizer
After a 2005 Supreme Court ruling against the homeowners, the entire neighborhood was bulldozed. This week Pfizer announced it is shutting down its research center. [includes rush transcript]
Tags: Pfizer Inc., New London, Giant Pfizer, Connecticut, eminent domain, Corporate crime, Dow Jones Industrial Average, Pfizer, Health Medical Pharma, Business Finance, Groton Connecticut, New London Connecticut, New London County Connecticut, Urban renewal, Kelo v. City of New London, Kelo, Politics, Redevelopment
A study of internal company documents suggests Pfizer Inc altered or omitted unfavorable study findings to expand its epilepsy drug Neurontin's market, U.S. researchers said on Wednesday, offering a look at how drugmakers influence scientific research....
Tags: Pfizer Inc., Neurontin
Reuters has reported that Johnson & Johnson plans to slash up to 7% of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to endure future challenges, the diversified healthcare company said last...
Tags: johnson & johnson, reuters, $1.4 to $1.7 billion, $800 to $900 million, chief executive officer william weldon, analysts, last major restructuring in 2007, 900 positions, ortho-mcneil-janssen pharmaceutical unit, risperdal, topamax, elan corporation, crucell, $970 million, cougar biotechnology, chief financial officer dominic caruso, centralization, pfizer inc., merck & co., bristol-myers squibb, glaxosmithkline, astrazeneca, shares, new york stock exchange
After successfully closing a merger with Wyeth last month, pharmaceutical colossus Pfizer (PFE) announced plans to close six of its research locations in an effort to consolidate the newly-expanded company’s research operations. “In less than a month,...
Tags: Wyeth, Pfizer Inc.
The world's biggest drugmaker is closing six of its 20 research facilities, reorganizing others, and cutting the jobs of roughly 15 percent of its scientists and support staff. The moves are part of Pfizer Inc.'s massive reorganization after buying drug...
Tags: Pfizer Inc., biotech drug, Wyeth, La Jolla, research facilities, giant pfizer, development operations, buying wyeth, traditional medicines
Pfizer Inc.'s traditional-medicines chief promised Friday that decisions about the company's research-and-development structure after its $66.9 billion merger with Wyeth Pharmaceuticals will be made decisively and implemented quickly. Martin Mackay, head...
Tags: Pfizer Inc., Wyeth Pharmaceuticals